Is Lipid Compatibility a Missing Piece in Primate-to-Human Lentivirus Jumps?
A discussion note with testable questions
Author: Andrew, an independent enquirer (not a virologist). Version 1, 6 November 2026.
1. Purpose and status of this note
This note sets out a small group of conjectures about the lipids of HIV and its primate ancestor SIV, and asks whether anyone has already tested them. It is written for readers who work on viral envelopes, membrane lipidomics, primate immunology or HIV cure research.
Status. The ideas are conjecture. They came out of a long exploratory conversation with a general-purpose AI search assistant, which agreed with everything I said and added claims I could not verify. I have since re-checked the literature claims below against published sources and removed the ones I could not support. Please treat every statement as a question for specialists, and correct me where I am wrong. Sources are listed in section 10.
Glossary.
| Term |
Meaning |
| SIV |
Simian immunodeficiency virus, the primate relatives of HIV |
| HERV |
Human endogenous retrovirus: ancient retroviral DNA permanently inside the human genome |
| Envelope |
The lipid skin around the virus, taken from the host cell when the virus buds off |
| CD1d |
A cell-surface molecule that shows lipids to a type of immune cell (iNKT cells, a kind of natural killer T cell) |
| Nef, Vpu |
HIV accessory proteins that interfere with host defences |
| 25HC |
25-hydroxycholesterol, a modified cholesterol made by the enzyme CH25H |
2. The core conjecture
HIV's envelope is host membrane. My conjecture has two parts:
- Subset hypothesis. SIV's envelope lipid profile may be close to a subset of what human cells can supply, so the virus finds a compatible lipid environment on crossing into humans.
- Incompatibility hypothesis. Where a lentivirus fails to cross into a new species ("wrong host"), part of the reason may be that the new host cannot supply a lipid environment the virus's proteins need.
I do not claim lipids are the main barrier. The best-documented barriers are protein-level (section 4). The question is whether lipid compatibility is a contributing, under-measured one.
3. What is established about HIV envelope lipids
- The envelope comes from the host. HIV buds from the host plasma membrane at raft-type sites (Brügger 2006; Scientific Reports 2016).
- It is not a plain copy of the host membrane. Mass spectrometry shows the virus is enriched in cholesterol and sphingomyelin, and its overall composition resembles detergent-resistant membrane domains and is strikingly different from the producer cells' membranes (Brügger 2006).
- The virus can shift its own lipid makeup. The presence of Nef during virus production raised sphingomyelin and lowered polyunsaturated phosphatidylcholine in virions, without a significant change in cholesterol (Brügger 2007). The authors found these changes insufficient to explain Nef's effect on infectivity.
- Envelope lipids matter for infection. Removing cholesterol from the virion reduces its ability to fuse with cells (PubMed 12239312; PMC516414).
Consequence for the subset hypothesis. Because the virus actively selects a raft-like composition, the sharper question is not "is SIV's lipid profile a subset of human lipids?" but "can a human producer cell, and a human target cell, supply and respond to the specific raft-like environment SIV's proteins evolved to use?"
4. What is established about cross-species barriers
The well-documented barriers are host restriction factors, which are cell proteins that block viral replication, and the viral proteins that counter them:
These are protein-level explanations. I have not found a study that tests lipid compatibility as a separate barrier. That is the gap this note points at, and I may have missed work that fills it.
5. A known lipid-based antiviral route (prior art)
I arrived at the idea of changing host lipids to block entry independently, and later found it is an active field:
- Interferon induces the enzyme CH25H, which makes 25HC. 25HC blocks membrane fusion by many enveloped viruses, including HIV. In humanized mice it suppressed HIV and reversed T-cell depletion, though it is hard to deliver in large doses (Liu et al., Immunity 2013; UCLA summary).
- Model-membrane work shows 25HC halves liposome fusion compared with cholesterol and alters the conformation of the HIV fusion peptide (Gomes et al., 2018).
Limits of this route. A single lipid change is not a permanent lockout. Cells keep making their own lipids, the virus can adapt, and because the envelope is host-made, anything that changes it also acts on healthy cells. The practical obstacle is collateral damage, which is why this has not become a mainstream treatment.
6. Second conjecture: primate CD1d and Nef
CD1d presents lipid antigens to iNKT cells. HIV-1 Nef and Vpu reduce CD1d at the cell surface. Nef does it by increasing internalisation and holding CD1d in the trans-Golgi network, and this depends on a tyrosine-based motif in CD1d's cytoplasmic tail (Chen et al., 2006; Vpu and Nef review). Vpu from some HIV-1 group N strains is largely unable to do this (NCBI gene summary).
My question. Do primate versions of CD1d differ in a way that matters for Nef and Vpu, and could that explain, or be copied to produce, a CD1d that HIV cannot suppress?
What the literature says so far.
- Function is highly conserved. Rhesus macaque iNKT cells bind and respond to human CD1d loaded with the standard lipid α-galactosylceramide (Yu et al.).
- A 2025 preprint reports the first macaque CD1d structure and finds a difference at one groove-capping residue (Phe84, fixed in macaque, flexible in human) alongside a conserved gating mechanism (Burns et al., preprint). That is a lipid-binding difference, not a Nef-binding one.
- Whether macaque or natural-host CD1d is resistant to SIV or HIV Nef and Vpu is, as far as I can find, not established. An AI answer I received claimed a specific human-versus-macaque difference in the cytoplasmic tail that blocks Nef. I could not confirm it, and I have not used it.
7. Third conjecture: lessons from natural hosts
African natural hosts of SIV, including sooty mangabeys, African green monkeys and mandrills, carry high viral loads without disease. The best-supported difference from HIV in humans is that they avoid chronic immune activation. They mount a strong early response and then actively dampen it (JCI commentary; mandrill study; Pasteur chapter). African green monkeys also show low CCR5 on CD4 cells, and low target-cell availability limits transmission to infants (PMC4019088).
My question. Is there a lipid or membrane component to how natural hosts dampen this response, and could copying natural-host tolerance be more productive than swapping individual molecules?
8. Fourth conjecture: lipid droplet architecture, and testable proposals
Lipid droplet architecture (hypothesis). Neighbouring cells with identical DNA differ in the number, size, position and contents of their lipid droplets. I conjecture this heterogeneity shapes how each cell responds to infection, including how much virus it produces. Cell-to-cell difference in gene activity and metabolic state is well established, so the new claim is only that droplet architecture is an important contributor. I have not surveyed the literature on lipid droplets in HIV infection, and I expect others have.
Proposed experiments (my suggestions, for specialists to improve or reject).
- Comparative envelope lipidomics. Produce SIV (for example SIVcpz or SIVsmm) and HIV-1 in matched primate and human CD4 T cells and macrophages. Measure lipids of the virions and of the producer plasma membrane by mass spectrometry, following Brügger 2006. Test whether the virion profile is conserved across hosts or follows the host.
- Does producer-cell lipid supply limit cross-species infectivity? Alter sphingomyelin, cholesterol or desaturation in producer cells, or use 25HC, and compare virion infectivity on primate and human target cells.
- CD1d tail swap. Express human CD1d with a primate cytoplasmic tail (and the reverse) in human cells, then test Nef and Vpu downregulation and iNKT activation.
- Droplet heterogeneity. Combine single-cell droplet imaging with infection outcome in primary CD4 T cells.
9. Ideas I have dropped
| Dropped claim |
Why |
| A single lipid change can lock HIV out of a cell for good |
Lipid balance is actively maintained and the virus adapts. |
| Lipid targeting is a "holy grail" because the virus cannot mutate around it |
Overstated. HIV adapts, and the envelope is host-made. |
| A specific macaque CD1d difference stops Nef, and gene-edited CD1d is in 2026 trials |
Not supported by anything I could find. |
| Making HIV a harmless "companion" of HERV as a treatment |
Becoming a permanent genome resident takes germline infection over very long timescales. |
| Conventional wisdom says neighbouring cells are identical |
A strawman. |
| Slogans such as "lipids are death" |
Lipids build every cell membrane. |
On HERVs. I include them only as background. Some ancient retroviral sequences were put to use (the placental protein syncytin is the best-known case), which shapes how I think about retroviruses as functional rather than purely harmful. It is not central to the questions above.
10. Sources
- Brügger B et al. The HIV lipidome: a raft with an unusual composition. PNAS 2006. https://pmc.ncbi.nlm.nih.gov/articles/PMC1413831
- Brügger B et al. HIV-1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology 2007. https://link.springer.com/content/pdf/10.1186/1742-4690-4-70.pdf
- Functional organization of the HIV lipid envelope. Sci Rep 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5039752
- Cholesterol in the HIV-1 membrane and fusion. https://pubmed.ncbi.nlm.nih.gov/12239312; also https://pmc.ncbi.nlm.nih.gov/articles/PMC516414
- Liu S-Y et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013. https://sigmaaldrich.com/PL/pl/tech-docs/paper/303783
- Gomes B et al. Effect of 25-hydroxycholesterol in viral membrane fusion: insights on HIV inhibition. BBA Biomembranes 2018. https://ri.conicet.gov.ar/handle/11336/94246
- Chen N et al. HIV-1 down-regulates the expression of CD1d via Nef. Eur J Immunol 2006. https://bvbvf1.bib-bvb.de/vufind/PrimoRecord/cdi_proquest_miscellaneous_67633308
- HIV-1 Vpu and Nef interfere with CD1d-mediated antigen presentation. https://pmc.ncbi.nlm.nih.gov/articles/PMC3412205
- Yu KKQ et al. Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates. https://rcastoragev2.blob.core.windows.net/eb00501d32ea11ab21dda99016abba04/PMC6647187.pdf
- Burns D et al. Ligand-responsive groove remodelling in human and macaque CD1d (preprint, Dec 2025). https://eprints.soton.ac.uk/510758/
- APOBEC3 and cross-species transmission of SIV (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC8228377
- APOBEC3G polymorphism as a barrier to cross-species transmission. https://pmc.ncbi.nlm.nih.gov/articles/PMC3789815
- Species-specific activity of SIV Nef and HIV-1 Vpu against tetherin. PLoS Pathog 2009. https://pmc.ncbi.nlm.nih.gov/articles/PMC2673686
- Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. https://pmc.ncbi.nlm.nih.gov/articles/PMC3444822
- Natural-host SIV infection and immune activation. JCI. https://jci.org/articles/view/41509; https://pmc.ncbi.nlm.nih.gov/articles/PMC3233116; https://research.pasteur.fr/en/b/BTs; https://pmc.ncbi.nlm.nih.gov/articles/PMC4019088
Links were located by web search on 6 November 2026. I read abstracts and summaries, not every full text, so please check details against the originals.